Medicinova vs Rallybio
Rallybio is the larger business, with $858,000 of revenue in fiscal 2025 against $409,657 for Medicinova (2.1 times as much). Rallybio grew faster (34.9% against -59.0%). Rallybio kept more of each dollar of sales as profit: a net margin of -1046.4% against -2928.8%. Medicinova carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | MedicinovaMNOV, 2025 | RallybioRLYB, 2025 |
|---|---|---|
| Revenue | $409,657 | $858,000 |
| Revenue growth | -59.0% | 34.9% |
| Net income | −$12.0m | −$9.0m |
| Operating margin | -3242.5% | -3853.6% |
| Net margin | -2928.8% | -1046.4% |
| Return on equity | -23.1% | -15.0% |
| Free cash flow | −$9.8m | −$29.8m |
| Cash | $30.8m | $31.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 14 |
| Market value | $70.9m | $85.2m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 1 sales | 14 buys, 2 sales |